Literature DB >> 4111773

C3 proactivator convertase and its mode of action.

H J Müller-Eberhard, O Götze.   

Abstract

The activity in human serum which is responsible for conversion of C3 proactivator (C3PA) to C3 activator was shown to reside in a 3S alpha-globulin. The factor, called C3PA convertase (C3PAse), was obtained in partially purified form. For conversion of C3PA, C3PAse required participation of metal ions and of a C3 fragment, which in physicochemical and antigenic properties resembled C3b. Isolated, native C3 failed to substitute for the fragment, but did restore the impaired C3 activator system in hydrazine-treated serum. Unlike native C3, the C3 fragment initiated conversion of C3PA in whole serum. A hypothetical concept which envisions the C3 fragment as effector of C3PAse has been proposed.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4111773      PMCID: PMC2139164          DOI: 10.1084/jem.135.4.1003

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

Review 1.  Complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Biochem       Date:  1969       Impact factor: 23.643

2.  Functional relationship of factor B in the properdin system to C3 proactivator of human serum.

Authors:  I Goodkofsky; I H Lepow
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

3.  Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system.

Authors:  O Götze; H J Müller-Eberhard
Journal:  N Engl J Med       Date:  1972-01-27       Impact factor: 91.245

4.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

5.  Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.

Authors:  C A Alper; N Abramson; R B Johnston; J H Jandl; F S Rosen
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

6.  Fluid phase destruction of C2hu by C1hu. II. Unmasking by C4ihu of C1hu specificity for C2hu.

Authors:  I Gigli; K F Austen
Journal:  J Exp Med       Date:  1969-10-01       Impact factor: 14.307

7.  Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement.

Authors:  I Gigli; A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-12-01       Impact factor: 14.307

8.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

  8 in total
  113 in total

1.  The effect of anticomplementary substances on properdin in normal and C2-deficient sera.

Authors:  R H McLean; K Townsend; A F Michael
Journal:  Clin Exp Immunol       Date:  1975-03       Impact factor: 4.330

2.  Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.

Authors:  S Ruddy; K F Austen; E J Goetzl
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

3.  Molecular mechanisms of complement evasion: learning from staphylococci and meningococci.

Authors:  Davide Serruto; Rino Rappuoli; Maria Scarselli; Piet Gros; Jos A G van Strijp
Journal:  Nat Rev Microbiol       Date:  2010-06       Impact factor: 60.633

Review 4.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

5.  Chylomicron accelerates C3 tick-over by regulating the role of factor H, leading to overproduction of acylation stimulating protein.

Authors:  Takayuki Fujita; Takayuki Fujioka; Tetsuo Murakami; Atsushi Satomura; Yoshinobu Fuke; Koichi Matsumoto
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

6.  Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors:  J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

7.  Isolation and characterization of rat complement factor B and its interaction with cell-bound human C3.

Authors:  M R Daha; L A van Es
Journal:  Immunology       Date:  1980-12       Impact factor: 7.397

8.  Complement activation by Coccidioides immitis: in vitro and clinical studies.

Authors:  J N Galgiani; P Yam; L D Petz; P L Williams; D A Stevens
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

9.  Inactivator of the third component of complement as an inhibitor in the properdin pathway.

Authors:  C A Alper; F S Rosen; P J Lachmann
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

10.  Sequence determination of the thiolester site of the fourth component of human complement.

Authors:  R A Harrison; M L Thomas; B F Tack
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.